|2nd September 2020||James R Tobin||5,600||Open or private sale||$56.85||$318,360.00|
|2nd September 2020||James R Tobin||5,600||Exercise of derivative||$26.27||$147,112.00|
|25th August 2020||James R Tobin||17,400||Exercise of derivative||$26.27||$457,098.00|
|25th August 2020||James R Tobin||17,400||Open or private sale||$54.40||$946,560.00|
|3rd August 2020||Ronald Asbury Andrews||40,000||Open or private purchase||$1.35||$53,880.00|
|24th June 2020||Andrew Scott Walton||4,081||Grant/award etc.||$0.00|
|24th June 2020||Ronald Asbury Andrews||4,081||Grant/award etc.||$0.00|
|24th June 2020||Herm Rosenman||4,081||Grant/award etc.||$0.00|
|24th June 2020||James R Tobin||4,081||Grant/award etc.||$0.00|
|24th June 2020||Richard A Sandberg||4,081||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Oxford Immunotec Global Plc develops and commercializes proprietary tests for immunology and infectious disease. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, UK.